Introduction
Annual reporting requirements MCQs With Answer is a focused quiz set designed for M.Pharm students to strengthen understanding of pharmacovigilance documentation and regulatory writing related to periodic safety reporting. This collection explains core concepts such as PBRER/PSUR, DSUR, expedited reporting timelines, signal detection, roles and responsibilities of marketing authorization holders and sponsors, and international guidance (ICH). Each question probes practical knowledge needed for preparing, reviewing and submitting annual and periodic safety reports. The questions emphasize regulatory intent, required content, timelines and the rationale behind aggregated benefit–risk evaluations to help students apply theory to real-world regulatory practice.
Q1. What is the primary objective of an annual/periodic safety report (e.g., PBRER)?
- To assess the ongoing benefit–risk profile of a medicinal product
- To summarize annual sales and market share
- To renew marketing authorisation paperwork
- To replace case by case adverse event reporting
Correct Answer: To assess the ongoing benefit–risk profile of a medicinal product
Q2. Which ICH guideline defines the Periodic Benefit–Risk Evaluation Report (PBRER)?
- ICH E2C(R2) – Periodic Benefit–Risk Evaluation Report (PBRER)
- ICH E2A – Clinical Safety Data Management
- ICH E3 – Clinical Study Report
- ICH M4 – Common Technical Document
Correct Answer: ICH E2C(R2) – Periodic Benefit–Risk Evaluation Report (PBRER)
Q3. Which report is intended specifically to provide an annual safety update during clinical development?
- Development Safety Update Report (DSUR)
- Periodic Safety Update Report (PSUR)
- Periodic Benefit–Risk Evaluation Report (PBRER)
- Annual Pharmacovigilance Summary (APS)
Correct Answer: Development Safety Update Report (DSUR)
Q4. The PBRER introduced in ICH E2C(R2) replaced which older reporting format?
- Periodic Safety Update Report (PSUR)
- Clinical Study Report (CSR)
- Development Safety Update Report (DSUR)
- Annual Report of Marketing Activities
Correct Answer: Periodic Safety Update Report (PSUR)
Q5. According to ICH E2A, what is the expedited reporting timeline for a fatal or life‑threatening SUSAR in clinical trials?
- 7 calendar days for initial report
- 15 calendar days for initial report
- 30 calendar days for initial report
- 90 calendar days for initial report
Correct Answer: 7 calendar days for initial report
Q6. For other serious unexpected suspected adverse reactions (non–life‑threatening), what is the ICH expedited reporting timeframe?
- 15 calendar days for initial report
- 7 calendar days for initial report
- 30 calendar days for initial report
- 60 calendar days for initial report
Correct Answer: 15 calendar days for initial report
Q7. Which of the following is NOT a standard component of a PBRER?
- Financial sales data and marketing budgets
- Cumulative and interval safety information
- Integrated benefit–risk analysis
- Conclusions and recommended actions
Correct Answer: Financial sales data and marketing budgets
Q8. Who is primarily responsible for preparing and submitting periodic safety reports for a marketed medicinal product?
- Marketing Authorisation Holder (MAH)
- Clinical trial investigator
- Contract research organization’s sales team
- Patient advocacy group
Correct Answer: Marketing Authorisation Holder (MAH)
Q9. What is the usual reporting frequency of the DSUR?
- Annual
- Quarterly
- Semi‑annually
- Only at end of development
Correct Answer: Annual
Q10. Which standardized form is commonly used internationally for expedited case safety reports?
- CIOMS I
- ICH E3
- MedDRA Primary Form
- ICH M4
Correct Answer: CIOMS I
Q11. Periodic reports support signal detection primarily through which approach?
- Aggregate analysis across multiple data sources
- Relying only on individual case reports without aggregation
- Comparing annual sales volumes
- Counting number of publications only
Correct Answer: Aggregate analysis across multiple data sources
Q12. The frequency at which a PBRER should be submitted is generally determined by:
- The product’s risk profile and regulatory requirements
- Monthly sales performance
- The company’s financial year
- Number of marketing authorisation holders worldwide
Correct Answer: The product’s risk profile and regulatory requirements
Q13. Which ICH guidance provides the recommended format and content for the DSUR?
- ICH E2F – Development Safety Update Report (DSUR)
- ICH E2C – Periodic Safety Update Report
- ICH E6 – Good Clinical Practice
- ICH M1 – MedDRA
Correct Answer: ICH E2F – Development Safety Update Report (DSUR)
Q14. In a PBRER, where are regulatory actions or recommendations typically documented?
- Conclusions and recommendations section
- Title page only
- Appendix for non‑clinical data only
- Cover letter without details
Correct Answer: Conclusions and recommendations section
Q15. Which of the following best describes a Periodic Safety Update Report (PSUR)?
- An earlier term for periodic post‑marketing safety reports now succeeded by PBRER in ICH regions
- A report exclusively for clinical trial sites
- A monthly vigilance newsletter for patients
- A financial audit of pharmacovigilance activities
Correct Answer: An earlier term for periodic post‑marketing safety reports now succeeded by PBRER in ICH regions
Q16. What primary data sources are integrated in a robust periodic safety report to evaluate benefit–risk?
- Individual case safety reports, aggregated analyses, clinical and epidemiological studies, and literature
- Only marketing materials and promotional claims
- Only non‑clinical toxicology reports
- Only annual financial statements
Correct Answer: Individual case safety reports, aggregated analyses, clinical and epidemiological studies, and literature
Q17. When a significant new safety signal is identified between reporting periods, the best immediate action is to:
- Validate and assess the signal, then notify regulators as required and include findings in the next periodic report
- Wait until the next annual report without interim actions
- Remove the product from all markets without analysis
- Publish marketing materials to reassure stakeholders
Correct Answer: Validate and assess the signal, then notify regulators as required and include findings in the next periodic report
Q18. For clinical trials, who is responsible for assembling and submitting the DSUR?
- The clinical trial sponsor
- The local study investigator only
- The site pharmacy
- The marketing authorisation buyer
Correct Answer: The clinical trial sponsor
Q19. Which report explicitly integrates benefit–risk assessment rather than focusing solely on safety events?
- Periodic Benefit–Risk Evaluation Report (PBRER)
- Individual Case Safety Report (ICSR)
- Case Narrative Only Report
- Marketing Status Report
Correct Answer: Periodic Benefit–Risk Evaluation Report (PBRER)
Q20. Which ICH standard governs the electronic transmission of Individual Case Safety Reports (ICSRs)?
- ICH E2B (electronic transmission of ICSRs)
- ICH E5 (ethnic factors)
- ICH S7 (pharmacology)
- ICH Q9 (quality risk management)
Correct Answer: ICH E2B (electronic transmission of ICSRs)
